This single arm, open-label, Phase 2 study will evaluate the safety and efficacy of Selinexor given orally at 60 mg/m2 twice weekly. Overall response rate is the primary endpoint of this study, which was designed based on data from the ongoing Phase 1 study of Selinexor in patients with advanced hematologic malignancies, including Richter's. This study is expected to take 2 years to complete.
"Richter's Transformation is a rare condition in which chronic lymphocytic leukemia transforms into a fast-growing type of aggressive lymphoma. Treatment options for these patients are limited and prognosis is generally poor, with median survival less than 10 months from diagnosis," said
"The initiation of our second registration-directed clinical study with Selinexor represents additional progress toward our goal of accelerating drug development for patients with severe hematologic indications with high unmet medical need," said
About Richter's Transformation
Richter's Transformation describes the appearance of an aggressive non-Hodgkin's lymphoma (NHL) in patients with chronic lymphocytic leukemia (CLL), or less commonly in patients with indolent lymphomas. There are about 1500 new cases of Richter's Transformation in
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound. Selinexor functions by inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. Over 450 patients have been treated with Selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors. Karyopharm has initiated two registration-directed clinical trials of Selinexor, one in older patients with acute myeloid leukemia and the other in patients with Richter's Transformation. Two additional registration-directed clinical trials in hematological indications, one in patients with diffuse large B-cell lymphoma (DLBCL) and the other in patients with multiple myeloma, are expected to begin enrollment during the fourth quarter of 2014 and first half of 2015, respectively. Additional Phase 1 and Phase 2 studies are ongoing or currently planned, including multiple investigator-sponsored studies of Selinexor in combination with one or more approved therapies. The latest clinical trial information for Selinexor is available at www.clinicaltrials.gov.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE™ compounds, including Selinexor (KPT-330), or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the
Justin Renz(617) 658-0574 email@example.com Gina Nugent(617) 460-3579 firstname.lastname@example.org
Source: Karyopharm Therapeutics
News Provided by Acquire Media